C-NUBHArrive Bio
in vivo screening, machine learning, bioinformatics
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-NUBH
C-NUBHC-NUBHin vivo screening, machine learning, bioinformatics
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Arrive Bio in vivo screening, machine learning, bioinformatics
Arrive is a biotechnology company applying in-vivo target screening with machine learning to age-related diseases. The company says it has developed a system to make in vivo target screening feasible by combining machine learning, bioinformatics, and a proprietary knowledge database. Its Coherence platform collects and synthesizes data to produce deep learning models for interpreting complex biologic data.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Arrive Bio — Far from goals · Bottom quartile. Derived deterministically from 2 extracted project(s). Most-advanced status: undisclosed. Band: far. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic